Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.

Le X, Sakai H, Felip E, Veillon R, Garassino MC, Raskin J, Cortot AB, Viteri S, Mazieres J, Smit EF, Thomas M, Iams WT, Cho BC, Kim HR, Yang JC, Chen YM, Patel JD, Bestvina CM, Park K, Griesinger F, Johnson M, Gottfried M, Britschgi C, Heymach J, Sikoglu E, Berghoff K, Schumacher KM, Bruns R, Otto G, Paik PK

Open source

DOI: 10.1158/1078-0432.ccr-21-2733
Published: 2022 Mar 15
Container: Clinical cancer research : an official journal of the American Association for Cancer Research
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-21-2733,
  title = {Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.},
  author = {Le X and Sakai H and Felip E and Veillon R and Garassino MC and Raskin J and Cortot AB and Viteri S and Mazieres J and Smit EF and Thomas M and Iams WT and Cho BC and Kim HR and Yang JC and Chen YM and Patel JD and Bestvina CM and Park K and Griesinger F and Johnson M and Gottfried M and Britschgi C and Heymach J and Sikoglu E and Berghoff K and Schumacher KM and Bruns R and Otto G and Paik PK},
  year = {2022},
  journal = {Clinical cancer research : an official journal of the American Association for Cancer Research},
  doi = {10.1158/1078-0432.ccr-21-2733},
  url = {https://doi.org/10.1158/1078-0432.ccr-21-2733}
}

RIS

TY  - JOUR
TI  - Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.
AU  - Le X
AU  - Sakai H
AU  - Felip E
AU  - Veillon R
AU  - Garassino MC
AU  - Raskin J
AU  - Cortot AB
AU  - Viteri S
AU  - Mazieres J
AU  - Smit EF
AU  - Thomas M
AU  - Iams WT
AU  - Cho BC
AU  - Kim HR
AU  - Yang JC
AU  - Chen YM
AU  - Patel JD
AU  - Bestvina CM
AU  - Park K
AU  - Griesinger F
AU  - Johnson M
AU  - Gottfried M
AU  - Britschgi C
AU  - Heymach J
AU  - Sikoglu E
AU  - Berghoff K
AU  - Schumacher KM
AU  - Bruns R
AU  - Otto G
AU  - Paik PK
PY  - 2022
JO  - Clinical cancer research : an official journal of the American Association for Cancer Research
DO  - 10.1158/1078-0432.ccr-21-2733
UR  - https://doi.org/10.1158/1078-0432.ccr-21-2733
ER  -

APA

X, L., H, S., E, F., R, V., MC, G., J, R., AB, C., S, V., J, M., EF, S., M, T., WT, I., BC, C., HR, K., JC, Y., YM, C., JD, P., CM, B., K, P., F, G., M, J., M, G., C, B., J, H., E, S., K, B., KM, S., R, B., G, O., & PK, P. (2022). Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.ccr-21-2733

Source records

pubmed · retrieved 2026-09-26T08:01:25.705Z